← All trials
NCT06671002
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2025
- Primary completion
- Jan 31, 2030
- Completion date
- Jan 31, 2030
- First posted
- Nov 4, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 900
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MichiganLead sponsor
- University of MichiganSponsor investigator
- Patient-Centered Outcomes Research InstituteCollaborator
- University of MichiganOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.